<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202786</url>
  </required_header>
  <id_info>
    <org_study_id>ONCO1miRviewmets</org_study_id>
    <nct_id>NCT01202786</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)</brief_title>
  <official_title>An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clalit Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rosetta Genomics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is in cancer of unknown primary (CUP) patients, to compare the&#xD;
      cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary&#xD;
      tumor site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thousands of patients are diagnosed each year with metastatic cancer; however, about 3-5% of&#xD;
      them are diagnosed with Cancer of Unknown Primary (CUP). In order to identify the optimal&#xD;
      treatment plan for individual patients with CUP, the primary tumor site must be identified.&#xD;
      Patients undergo a wide range of costly, time-consuming, and inefficient tests to identify&#xD;
      the primary site of origin, often to no avail.&#xD;
&#xD;
      In this era of targeted therapies, the accurate diagnosis of the primary tumor can be&#xD;
      crucial. miRview™ mets is a new molecular diagnostic tool that identifies the&#xD;
      tissue-of-origin of metastatic tumors, with 90% sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>18 months</time_frame>
    <description>To compare the cost-effectiveness of miRview™ mets test with conventional work-up in cancer of unknown primary (CUP) patients, by comparing total cost and time of the diagnostic process (including hospitalization time) from day 1 of the study to the decision on treatment program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare the diagnostic performance</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluating the miRview™ mets results based on the clinical and pathological work-up in all patients (retrospectively).&#xD;
Evaluating the concordance between miRview™ mets result and the diagnosis obtained by the standard work-up process.&#xD;
Comparing the response to treatment between study groups.&#xD;
Comparing overall survival between study groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Neoplasms, Unknown Primary</condition>
  <arm_group>
    <arm_group_label>miRview mets Disclosed</arm_group_label>
    <description>Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin Fixed Paraffin Embedded tumor tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who present with histologically-confirmed metastatic cancer in whom an initial&#xD;
        work-up which consists of detailed medical history, physical examination, basic laboratory&#xD;
        studies, histopathological review of biopsy material, and CT scan of the chest abdomen and&#xD;
        pelvis fail to identify the primary site.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who present with histologically-confirmed metastatic cancer in whom an&#xD;
             initial work-up which consists of detailed medical history, physical examination,&#xD;
             basic laboratory studies, histopathological review of biopsy material, and CT scan of&#xD;
             the chest abdomen and pelvis fail to identify the primary site.&#xD;
&#xD;
          2. Older than 18 years&#xD;
&#xD;
          3. Performance status &lt;2&#xD;
&#xD;
          4. life expectancy &gt;3 months&#xD;
&#xD;
          5. ANC &gt;1500&#xD;
&#xD;
          6. Platelets &gt;100,000 if bone marrow is not involved&#xD;
&#xD;
          7. Hb &gt; 9&#xD;
&#xD;
          8. Creatinine &lt;2&#xD;
&#xD;
          9. LFTS &lt; x5 normal&#xD;
&#xD;
         10. Histology proven of malignancy&#xD;
&#xD;
         11. Enough material for miRview test (10 slices of 10 micrometer sections)&#xD;
&#xD;
         12. Member of Clalit HMO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable or unwilling to sign the informed consent form&#xD;
&#xD;
          2. Under 18 years old&#xD;
&#xD;
          3. Performance status &gt;2&#xD;
&#xD;
          4. life expectancy&lt;3 months&#xD;
&#xD;
          5. ANC &lt;1500&#xD;
&#xD;
          6. Platelets &lt;100,000 if marrow not involved&#xD;
&#xD;
          7. Hb &lt; 9&#xD;
&#xD;
          8. Creatinine &gt;2&#xD;
&#xD;
          9. LFTS &gt; x5 normal&#xD;
&#xD;
         10. Not member of Clalit HMO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salomon Shtemmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ha'emek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer of Unknown Primary Site (CUP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

